#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small cell lung cancer limited stage Small intestine neuroendocrine tumour Diffuse large B-cell lymphoma Chronic graft versus host disease in skin Growth hormone deficiency Leukaemia Oropharyngeal squamous cell carcinoma Obesity Congenital myopathy Desmoid tumour Richter's syndrome Hepatoblastoma Renal cancer metastatic Pseudomyxoma peritonei Raynaud's phenomenon More trials…

    Learn about Rare Diseases

    Basal cell naevus syndrome – Diagnostics Congenital generalised lipodystrophy Lysosomal storage disorder – Treatment Immunodeficiency congenital – Basic Information Haemophilia B without inhibitors – Trials in Disease Chronic granulomatous disease – Treatment Loeys-Dietz syndrome – Life with Disease Glycogen storage disease type II – Treatment Retinitis pigmentosa – Trials in Disease Haemolytic uraemic syndrome – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ucp2 Cariprazine Potassium Chloride Mifamurtide Dacomitinib Teriparatide ANUMIGILIMAB Cetirizine Tetracosactide Azenosertib OMTX705 Ecoo2 ADS-019 Pralatrexate Psilocybine Amniotic Membrane, Human PRILOCAINE HYDROCHLORIDE Phenylephrine 2-DEOXY-D-GLUCOSE Calcitriol More therapies…

    Learn about Your Condition

    Supraventricular tachycardia Colorectal cancer stage II Primary biliary cholangitis Cerebellar ataxia Anaemia of pregnancy Red blood cell abnormality Systemic scleroderma Thalassaemia Muscle injury Gastrooesophageal cancer Ovarian cancer recurrent Cardiac amyloidosis Ebola disease Hodgkin's disease Seasonal allergy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rath Gyorgy Utca 7-9, Kerulet, Budapest, 1122, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Docetaxel
    • Infliximab
    Austria Belgium Denmark Finland France Germany +7

  • Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Head and neck cancer
    Investigated Drugs:
    • HAFNIUM OXIDE
    • Cetuximab
    Austria Belgium Czechia France Germany Greece +4

  • Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Cimetidine Hydrochloride
    • Buclizine Hydrochloride
    • Carboplatin
    Austria Belgium Czechia Denmark Finland France +10

  • Study on How Bevacizumab Affects the Immune System in Patients with Glioblastoma Multiforme

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Glioblastoma multiforme
    Investigated Drugs:
    • Bevacizumab
    Hungary

  • Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive gastric cancer
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Fluorouracil
    Austria Belgium France Germany Hungary Italy +3

  • Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • BNT327
    • Carboplatin
    • Paclitaxel
    Belgium Bulgaria France Germany Hungary Italy +3

  • Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Buclizine Hydrochloride
    • Codeine Phosphate
    Austria Belgium Czechia Denmark Finland France +8

  • Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Zilovertamab Vedotin
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    Belgium Denmark France Greece Hungary Italy +5

  • Study comparing Rilvegostomig plus chemotherapy versus Pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Infliximab
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • 5,8-Dichloro-2-[(4-Methoxy-6-Methyl-2-Oxo-1,2-Dihydropyridin-3-Yl)Methyl]-7-[(R)-Methoxy(Oxetan-3-Yl)Methyl]-3,4-Dihydroisoquinolin-1(2H)-One
    • Enzalutamide
    Bulgaria Czechia Denmark Finland France Germany +8
Previous Page
1 2 3 4 5 6 … 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!